Venus Remedies bags market authorisation for Bleomycin 15,000 IU in UK
Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulfate, specifically designed to combat cancer
Venus Remedies has announced the achievement of market authorisation in the UK for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion by its German subsidiary, Venus Pharma. This remarkable milestone not only expands the pharma giant’s global presence but also underscores its commitment to advancing cancer care with innovative solutions.
Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulfate. It belongs to a group of medicines known as cytostatic drugs, specifically designed to combat cancer. This class of medications, often referred to as chemotherapy, is renowned for its effectiveness in targeting cancer cells and preventing their uncontrolled division.
Its versatile applications include the treatment of certain types of squamous cell carcinomas in the head and neck, cervix, and external genitalia. It also serves as a panacea in treating severe types of lymph node cancers, such as Hodgkin’s disease and non-Hodgkin’s lymphoma of intermediate and high malignancy, testicular cancer, and fluid accumulation in the lungs, often associated with cancer.
Bleomycin can be administered as a standalone treatment or in combination with other cancer medications and radiotherapy. Its effectiveness and utility in cancer treatment have earned it market authorisations in numerous countries worldwide.
“At Venus, our mission is to improve the lives of cancer patients by providing cutting-edge treatments. The UK’s market authorization for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion is a significant step towards realising this mission. We remain dedicated to enhancing healthcare solutions and are committed to pursuing additional authorisations to reach even more patients in need,” stated Saransh Chaudhary, CEO, Venus Medicine Research Center (VMRC).
Ashutosh Jain, CEO, Venus Pharma, expressed that obtaining market authorisation from MHRA is a momentous accomplishment for Venus Pharma GmbH. It enables the company to play a pivotal role in advancing cancer care and improving the quality of life for patients facing this challenging disease.
